A placebo-controlled trial testing dasatinib plus quercetin in postmenopausal women with low bone density revealed marginal improvements in bone formation markers and trabecular bone score, though overall bone mineral density changes remained within statistical noise. The 12-week intervention targeted senescent cells theoretically contributing to age-related bone loss through inflammatory signaling pathways. This represents the first rigorous human data on senolytics for skeletal health, an area where cellular senescence has been implicated through animal studies showing dramatic bone rescue effects. The modest human results align with a broader pattern emerging across senolytic research: while cellular aging mechanisms are well-established in laboratory settings, translating these insights into clinically meaningful human interventions proves considerably more complex. The bone microenvironment involves intricate interactions between osteoblasts, osteoclasts, and immune cells that may not respond as predictably to senescent cell clearance as simpler tissue models suggest. For women facing osteoporosis risk, these findings suggest senolytics alone are insufficient as primary interventions, though they might eventually serve as adjunct therapies within comprehensive bone health strategies combining traditional approaches with emerging cellular aging treatments.